Compare Stocks → The Small Biotech with a BIG Cancer Solution (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALPNNASDAQ:ITRMNASDAQ:MACKNASDAQ:TRVI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPNAlpine Immune Sciences$38.65+3.2%$31.57$6.71▼$42.88$2.45B1.131.29 million shs787,120 shsITRMIterum Therapeutics$1.59+1.9%$1.55$0.62▼$2.50$20.96M2.35196,075 shs144,483 shsMACKMerrimack Pharmaceuticals$14.75+0.2%$14.23$11.53▼$15.89$213.91M1.4499,768 shs95,075 shsTRVITrevi Therapeutics$3.47+2.4%$2.41$0.97▼$4.00$233.77M0.85312,212 shs90,476 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPNAlpine Immune Sciences+3.20%-3.93%+11.22%+97.60%+435.32%ITRMIterum Therapeutics+1.92%+0.63%+24.22%-20.50%+67.37%MACKMerrimack Pharmaceuticals+0.20%+0.41%+0.34%+10.65%+21.90%TRVITrevi Therapeutics+2.36%-1.98%+28.04%+149.64%+92.78%Warning: this could blow your mind (Ad)Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALPNAlpine Immune Sciences1.4836 of 5 stars2.51.00.00.03.84.20.0ITRMIterum Therapeutics1.372 of 5 stars3.52.00.00.02.30.00.6MACKMerrimack Pharmaceuticals1.0971 of 5 stars0.03.00.00.02.65.00.0TRVITrevi Therapeutics3.4043 of 5 stars3.55.00.00.03.23.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPNAlpine Immune Sciences3.00Buy$38.860.54% UpsideITRMIterum Therapeutics3.00Buy$6.00277.36% UpsideMACKMerrimack PharmaceuticalsN/AN/AN/AN/ATRVITrevi Therapeutics3.00Buy$7.67120.94% UpsideCurrent Analyst RatingsLatest ALPN, TRVI, MACK, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/21/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/19/2024ALPNAlpine Immune SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $47.003/19/2024ALPNAlpine Immune SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$47.003/19/2024ALPNAlpine Immune SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $44.003/19/2024ALPNAlpine Immune SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $50.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/15/2024ALPNAlpine Immune SciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$44.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.001/26/2024ALPNAlpine Immune SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $35.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPNAlpine Immune Sciences$58.88M43.03N/AN/A$5.64 per share6.85ITRMIterum TherapeuticsN/AN/AN/AN/A$2.29 per shareN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ATRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)ITRMIterum Therapeutics-$44.43M-$2.44N/AN/AN/AN/A-216.28%-57.67%3/28/2024 (Confirmed)MACKMerrimack Pharmaceuticals-$1.18M-$0.08N/A∞N/AN/A-6.24%-6.09%5/2/2024 (Estimated)TRVITrevi Therapeutics-$29.07M-$0.29N/AN/AN/AN/A-31.51%-28.89%5/9/2024 (Estimated)Latest ALPN, TRVI, MACK, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024N/AITRMIterum Therapeutics-$1.02N/A+$1.02N/AN/AN/A 3/7/2024Q4 2023MACKMerrimack PharmaceuticalsN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPNAlpine Immune SciencesN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPNAlpine Immune SciencesN/A7.867.86ITRMIterum Therapeutics3.632.352.35MACKMerrimack PharmaceuticalsN/A43.5043.50TRVITrevi TherapeuticsN/A15.0315.03OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPNAlpine Immune Sciences75.17%ITRMIterum Therapeutics9.21%MACKMerrimack Pharmaceuticals63.97%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipALPNAlpine Immune Sciences42.30%ITRMIterum Therapeutics5.40%MACKMerrimack Pharmaceuticals28.87%TRVITrevi Therapeutics27.46%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALPNAlpine Immune Sciences12665.55 million37.82 millionOptionableITRMIterum Therapeutics1413.44 million12.71 millionNot OptionableMACKMerrimack Pharmaceuticals42614.53 million10.34 millionOptionableTRVITrevi Therapeutics2568.96 million50.02 millionOptionableALPN, TRVI, MACK, and ITRM HeadlinesSourceHeadlineProminent Trevi Italian Restaurant Abruptly Closes at the Forum Shopsmsn.com - March 27 at 1:26 PMTrevi Therapeutics, Inc. (NASDAQ:TRVI) to Post FY2025 Earnings of ($0.60) Per Share, Leerink Partnrs Forecastsamericanbankingnews.com - March 25 at 3:04 AMTrevi Therapeutics (NASDAQ:TRVI) Stock Rating Reaffirmed by Oppenheimeramericanbankingnews.com - March 22 at 7:06 AMTrevi Therapeutics (NASDAQ:TRVI) Stock Rating Reaffirmed by Needham & Company LLCamericanbankingnews.com - March 22 at 6:22 AMTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 21 at 11:14 AMOppenheimer Reaffirms "Outperform" Rating for Trevi Therapeutics (NASDAQ:TRVI)marketbeat.com - March 21 at 9:38 AMTrevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updatesfinanznachrichten.de - March 21 at 7:22 AMTrevi Therapeutics: Q4 Earnings Insightsbenzinga.com - March 20 at 9:21 PMTRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023msn.com - March 20 at 9:21 PMTrevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trialsfinance.yahoo.com - March 20 at 9:21 PMTrevi Therapeutics (TRVI) Set to Announce Earnings on Wednesdayamericanbankingnews.com - March 18 at 1:56 AMGloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With Nebulossamsn.com - March 17 at 10:44 PMGloria Trevi Lights Up New York, Debuts ‘Zorra’ Remix With Nebulossamsn.com - March 16 at 4:38 PMWhat happens to the coins tossed into Rome's Trevi Fountain?astroawani.com - March 15 at 11:04 PMTrevi Therapeutics (TRVI) Set to Announce Quarterly Earnings on Wednesdaymarketbeat.com - March 14 at 3:33 PMTrevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024finance.yahoo.com - March 13 at 8:28 PMVista Shaw, The Spectrum, Wil Tower, and Laureano di Trevi Towers unveil big-cut unitsbworldonline.com - March 13 at 3:27 PMVisitors' coins in Rome's Trevi Fountain provide practical help to Italiansabc.net.au - March 8 at 2:02 PMOne million Euro gets thrown into Rome’s Trevi Fountain each year. What happens next?msn.com - March 7 at 10:39 AMprivate equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last weekfinance.yahoo.com - February 29 at 10:35 AMTrevi Therapeutics to Participate in Upcoming March Eventsfinance.yahoo.com - February 28 at 7:37 AMTrevi Therapeutics to Participate in Upcoming March Eventsprnewswire.com - February 28 at 7:30 AMTrevi Therapeutics Inc.thestreet.com - February 24 at 9:36 AMTRVI Mar 2024 2.000 callfinance.yahoo.com - February 22 at 11:20 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAlpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Merrimack PharmaceuticalsNASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Trevi TherapeuticsNASDAQ:TRVITrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.